MGMT promoter methylation

These advances underscore the transformative potential of biomarker-guided precision radiotherapy, enabling tailored interventions that counteract resistance mechanisms and synergize with immunotherapies. By bridging molecular insights with clinical innovation, this paradigm shift promises to redefine glioma management, offering renewed hope for overcoming therapeutic recalcitrance in this devastating malignancy.

We provide empirical evidence supporting a role for histo-morphological and limited molecular testing in neuro-oncology practice in LMICs.

All results significantly exceeded the performance of conventional CEST quantification techniques and existing deep learning-based models developed for CEST analysis (p < 0.05). MixBranchNet establishes a methodological foundation for spatial-spectral deep learning in CEST MRI and demonstrates encouraging performance for glioma segmentation and genotype prediction within the current single-center cohort.

This case represents the first documented instance of primary gliosarcoma with FDCS differentiation, thereby expanding its known differentiation spectrum. Furthermore, it demonstrates the necessity of separately analyzing each histological component in the diagnosis of challenging cases.

However, current standard of care treatments such as surgical resection, radiotherapy, temozolomide, and tumor treating fields have reached a therapeutic plateau, highlighting the urgent need for new therapeutic strategies...We further synthesize recent advances in spatial and longitudinal profiling technologies to describe the dynamic tumor immune ecosystem. We discuss how spatial compartmentalization and evolutionary processes collectively drive immune escape and therapeutic resistance, and highlight emerging strategies including adaptive immunotherapy, precision targeted delivery, and multimodal monitoring to overcome these challenges.

Our work presents a detailed analysis of a large series of IDH-mutant astrocytomas, underscoring the prognostic importance of WHO grade 4, tumor volume, and EOR.

P1, N=9, Recruiting, Masonic Cancer Center, University of Minnesota

Conclusion The multimodal model showed good performance for glioblastoma survival prediction and enabled time-dependent model interpretability, identifying the imaging-derived prognostic index as a complementary biomarker with sustained prognostic importance over time.

BEV monotherapy emerges as a promising treatment for rGBM, with favorable outcomes in biopsy results, corticosteroid use, PFS, and OS. Future research is needed to confirm these findings and optimize BEV's clinical application, emphasizing tailored treatment strategies to improve patient prognosis.

This limited contribution likely reflects the fact that synthetic PET is derived from MRI and cannot capture true tracer-driven metabolic or molecular information. These findings highlight the need to validate information complementarity before integrating synthesized modalities into clinical workflows.

This dataset offers a valuable resource for exploring the relationship between MRI characteristics and tumor genetics. It also serves as a robust benchmark for developing and validating DL models for various downstream tasks.

P1, N=56, Active, not recruiting, Dana-Farber Cancer Institute | Recruiting --> Active, not recruiting